JP2019142972A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019142972A5 JP2019142972A5 JP2019091047A JP2019091047A JP2019142972A5 JP 2019142972 A5 JP2019142972 A5 JP 2019142972A5 JP 2019091047 A JP2019091047 A JP 2019091047A JP 2019091047 A JP2019091047 A JP 2019091047A JP 2019142972 A5 JP2019142972 A5 JP 2019142972A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- administration
- tapentadol
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 28
- KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 claims description 10
- 229960005126 tapentadol Drugs 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 208000002193 Pain Diseases 0.000 claims description 4
- 206010058019 Cancer Pain Diseases 0.000 claims description 2
- 208000004550 Postoperative Pain Diseases 0.000 claims description 2
- 230000003444 anaesthetic effect Effects 0.000 claims description 2
- 239000003405 delayed action preparation Substances 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 238000007914 intraventricular administration Methods 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 238000007910 systemic administration Methods 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021195330A JP2022033863A (ja) | 2011-03-04 | 2021-12-01 | タペンタドールの非経口的投与 |
| JP2023037505A JP2023075244A (ja) | 2011-03-04 | 2023-03-10 | タペンタドールの非経口的投与 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161449317P | 2011-03-04 | 2011-03-04 | |
| US61/449,317 | 2011-03-04 | ||
| EP11003602 | 2011-05-03 | ||
| EP11003602.7 | 2011-05-03 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017158324A Division JP6837944B2 (ja) | 2011-03-04 | 2017-08-21 | タペンタドールの非経口的投与 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021195330A Division JP2022033863A (ja) | 2011-03-04 | 2021-12-01 | タペンタドールの非経口的投与 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019142972A JP2019142972A (ja) | 2019-08-29 |
| JP2019142972A5 true JP2019142972A5 (fi) | 2019-10-10 |
Family
ID=67771858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019091047A Pending JP2019142972A (ja) | 2011-03-04 | 2019-05-14 | タペンタドールの非経口的投与 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2019142972A (fi) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4011369A1 (en) * | 2020-12-14 | 2022-06-15 | G.L. Pharma GmbH | Aqueous pharmaceutical composition comprising tapentadol tartrate |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8334422D0 (en) * | 1983-12-23 | 1984-02-01 | Sterwin Ag | Composition |
| US6399087B1 (en) * | 2000-12-20 | 2002-06-04 | Amphastar Pharmaceuticals, Inc. | Propofol formulation with enhanced microbial inhibition |
| EP1893190A4 (en) * | 2005-04-28 | 2010-07-28 | Theraquest Biosciences Llc | METHODS AND COMPOSITIONS FOR TREATING PAIN |
| EP1905440A1 (de) * | 2006-09-06 | 2008-04-02 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verwendung einer pharmazeutischen Zusammensetzung enthaltend ein Anticholinergikum zur Abtötung von Mikroorganismen und zur Behandlung von Atemwegsinfektionen |
| DE102007012165A1 (de) * | 2007-03-12 | 2008-09-18 | Grünenthal GmbH | Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes |
| JP2008266168A (ja) * | 2007-04-18 | 2008-11-06 | Teika Seiyaku Kk | 眼科用剤 |
| EP2246044A1 (en) * | 2009-04-21 | 2010-11-03 | Pierre Fabre Dermo-Cosmétique | Paediatric solutions comprising a beta-blocker |
-
2019
- 2019-05-14 JP JP2019091047A patent/JP2019142972A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014510067A5 (fi) | ||
| JP7159277B2 (ja) | 即効型インスリン組成物 | |
| US10799466B2 (en) | Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief | |
| JP7133070B2 (ja) | ベンダムスチンの製剤 | |
| FI3506886T3 (fi) | Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä | |
| JP2022033863A (ja) | タペンタドールの非経口的投与 | |
| FI3340966T3 (fi) | Nopeavaikutteisia insuliinikoostumuksia | |
| JP2013535422A5 (fi) | ||
| JP2021143209A5 (fi) | ||
| TWI674899B (zh) | 醫藥配方 | |
| CN107073007A (zh) | 具有改进的稳定性的罗库溴铵制剂 | |
| JP2019537589A5 (fi) | ||
| DE102012010774A1 (de) | Pharmazeutische Pemetrexed-Lösung | |
| JP2019142972A5 (fi) | ||
| JP2020531568A5 (fi) | ||
| KR20200018438A (ko) | 향상된 용해도의 약물-함유 제형 | |
| JP2019142972A (ja) | タペンタドールの非経口的投与 | |
| WO2015157212A1 (en) | Stable apomorphine composition and uses thereof | |
| WO2011063604A1 (zh) | 一种化合物/氯化钠制剂 | |
| KR20140025369A (ko) | 히알루론산 또는 히알루론산염을 포함하는 수용액 | |
| KR20140050593A (ko) | 히알루론산 또는 히알루론산염을 포함하는 수용액 | |
| Niederlehner et al. | Comparison of bupivacaine and lidocaine: general anesthetic potency and therapeutic index | |
| JP2022085199A (ja) | ロクロニウム製剤 | |
| KR20140024863A (ko) | 히알루론산 또는 히알루론산염을 포함하는 수용액 | |
| JP2023507890A (ja) | メシル酸ジヒドロエルゴタミン製剤およびその治療的送達のための事前充填注射器 |